ADVFN Logo
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
Kiniksa Pharmaceuticals International PLC

Kiniksa Pharmaceuticals International PLC (KNSA)

22.35
0.74
(3.42%)
Closed July 16 4:00PM
22.35
0.00
( 0.00% )
Pre Market: 4:05AM

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
22.35
Bid
22.35
Ask
26.00
Volume
-
0.00 Day's Range 0.00
14.12 52 Week Range 22.65
Market Cap
Previous Close
22.35
Open
-
Last Trade
Last Trade Time
-
Financial Volume
-
VWAP
-
Average Volume (3m)
368,412
Shares Outstanding
70,940,145
Dividend Yield
-
PE Ratio
112.59
Earnings Per Share (EPS)
0.2
Revenue
270.26M
Net Profit
14.08M

About Kiniksa Pharmaceuticals International PLC

Kiniksa Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. Its clinical-stage product candidates include Rilonacept, for the treatment of recurre... Kiniksa Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. Its clinical-stage product candidates include Rilonacept, for the treatment of recurrent pericarditis, a debilitating inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; Vixarelimab; and KPL-404. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
Headquarters
London, Gbr
Founded
1970
Kiniksa Pharmaceuticals International PLC is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker KNSA. The last closing price for Kiniksa Pharmaceuticals was $22.35. Over the last year, Kiniksa Pharmaceuticals shares have traded in a share price range of $ 14.12 to $ 22.65.

Kiniksa Pharmaceuticals currently has 70,940,145 shares outstanding. The market capitalization of Kiniksa Pharmaceuticals is $1.59 billion. Kiniksa Pharmaceuticals has a price to earnings ratio (PE ratio) of 112.59.

KNSA Latest News

Kiniksa Pharmaceuticals to Report Second Quarter 2024 Financial Results on July 23, 2024

LONDON, July 16, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, July 23, 2024...

Kiniksa Pharmaceuticals Commences Enrollment in Abiprubart Phase 2b Clinical Trial in Sjögren’s Disease

– Abiprubart Phase 2b clinical trial in Sjögren’s Disease to evaluate treatment response across biweekly and monthly subcutaneous administrations – – Abiprubart clinical development in Sjögren’s...

Kiniksa Pharmaceuticals Partners with NHL Hall-of-Famer Henrik Lundqvist to Raise Awareness of Recurrent Pericarditis

– Campaign to elevate experiences from the recurrent pericarditis community and provide resources to patients and caregivers – HAMILTON, Bermuda, June 24, 2024 (GLOBE NEWSWIRE) -- Kiniksa...

Kiniksa Pharmaceuticals Sponsors American Heart Association’s Addressing Recurrent Pericarditis Initiative

– Initiative aimed at improving access and outcomes for patients with recurrent pericarditis – – American Heart Association to work with champions at 15 healthcare sites to implement initiative...

Kiniksa Pharmaceuticals to Present at Goldman Sachs 45th Annual Global Healthcare Conference

HAMILTON, Bermuda, June 04, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the Goldman Sachs 45th...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
12.019.8820058997120.3422.6520.0448561621.48971829CS
44.1923.072687224718.1622.6517.3846289219.64518773CS
124.1422.734761120318.2122.6517.3836841219.33375017CS
264.0922.398685651718.2622.6516.5636368419.32879829CS
527.7452.97741273114.6122.6514.1242165818.25244965CS
1568.864.944649446513.5522.657.3639022314.56466057CS
2608.4560.791366906513.9335.0136633015.49426617CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
SHIMShimmick Corporation
$ 3.15
(52.17%)
513.36k
APVOAptevo Therapeutics Inc
$ 0.4905
(46.42%)
4.63M
ADVMAdverum Biotechnologies Inc
$ 11.30
(26.68%)
59.48k
ALSAAlpha Star Acquisition Corporation
$ 12.25
(17.22%)
5
AFARAura FAT Projects Acquisition Corporation
$ 14.60
(16.80%)
17.4k
FIVEFive Below Inc
$ 88.10
(-13.69%)
7.72k
ESPREsperion Therapeutics Inc
$ 2.46
(-9.89%)
35.51k
SILOSilo Pharma Inc
$ 2.16
(-9.62%)
134.02k
MIRAMIRA Pharmaceuticals Inc
$ 0.7401
(-8.63%)
1
LCFYLocafy Ltd
$ 4.98
(-8.62%)
2.67k
APVOAptevo Therapeutics Inc
$ 0.4905
(46.42%)
4.63M
SQQQProShares UltraPro Short QQQ
$ 7.745
(3.82%)
609.53k
NVDANVIDIA Corporation
$ 122.89
(-2.75%)
558.94k
SHIMShimmick Corporation
$ 3.15
(52.17%)
513.36k
MAXNMaxeon Solar Technologies Ltd
$ 0.2439
(-3.37%)
512.77k